LEVILACTOBACILLUS BREVIS: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Levilactobacillus brevis (L. brevis) is a type of probiotic ("good" bacteria) found naturally in the human body. It's also found in fermented foods.

"Good" bacteria such as L. brevis might help the body break down food, absorb nutrients, and fight off "bad" organisms that might cause diseases. These bacteria are sometimes added to fermented foods like yogurt and also found in dietary supplements.

People use L. brevis for alcohol-related liver disease, overgrowth of bacteria in the vagina (bacterial vaginosis), common cold, dry skin, gum disease, insomnia, and many other conditions, but there is no good scientific evidence to support these uses.

Don't confuse L. brevis with other probiotics, or with fermented food products such as fermented milk, kefir, or yogurt. These are not the same. Also note that L. brevis used to be classified under the Lactobacillus genus. But Lactobacillus was split up into 25 different genera in April 2020. Some product labels might still list this species as Lactobacillus brevis rather than its new name, Levilactobacillus brevis.

Uses & Effectiveness

We currently have no information for LEVILACTOBACILLUS BREVIS overview.

Side Effects

When taken by mouth: L. brevis is possibly safe for most people. L. brevis has been used safely in doses of up to 12 billion colony-forming units (CFUs) daily for up to 3 months. It seems to be well-tolerated. But there isn't enough reliable information to know if heat-killed L. brevis is safe or what the side effects might be.

When applied to the vagina: L. brevis is possibly safe. It's been used safely in doses of up to 2 billion CFUs twice daily for 6 months.

Special Precautions and Warnings

Pregnancy and breast-feeding: There isn't enough reliable information to know if L. brevis is safe to use when pregnant or breast-feeding. But there are no reasons to expect safety concerns when used appropriately.

Children: L. brevis is possibly safe in most children when taken by mouth appropriately. It's been used safely in children 4-14 years-old in doses of up to 4 billion colony-forming units (CFUs) daily for up to 2 months or 10 billion CFUs for 4 weeks. There isn't enough reliable information to know if L. brevis is safe for very small premature infants. Also, there isn't enough reliable information to know if heat-killed L. brevis is safe or what the side effects might be.

Weakened immune system: Probiotics have caused blood infections in a small number of people with weakened immune systems. If you have a weakened immune system, talk with your healthcare provider before taking probiotics, including L. brevis.

Damaged heart valves: Probiotic preparations can cause an infection in the inner lining of the heart chambers and heart valve. This is extremely rare, but people with damaged heart valves should stop taking probiotics, including L. brevis, before dental procedures or surgical procedures.

Interactions

Moderate Interaction

Be cautious with this combination

Antibiotic drugs interacts with LEVILACTOBACILLUS BREVIS
L. brevis is a type of friendly bacteria. Antibiotics are used to reduce harmful bacteria in the body. Taking antibiotics along with L. brevis can reduce the effects of L. brevis. To avoid this interaction, take L. brevis products at least 2 hours before or after antibiotics.

Dosing

In adults, L. brevis has most often been taken by mouth alone or together with other probiotics in doses of 1-10 billion colony-forming units (CFUs) daily for 1-4 months. It's most often been applied to the vagina in doses of 4 billion CFUs daily for 6 months. It's also been used in gels and creams. Speak with a healthcare provider to find out what type of product and dose might be best for a specific condition.

View References

REFERENCES:

Aaron JG, Sobieszczyk ME, Weiner SD, Whittier S, Lowy FD. Lactobacillus rhamnosus endocarditis after upper endoscopy. Open Forum Infect Dis 2017;4(2):ofx085. View abstract.

Bertelli C, Pillonel T, Torregrossa A, et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 2015;60(6):924-7. View abstract.

Campus G, Cocco F, Carta G, et al. Effect of a daily dose of Lactobacillus brevis CD2 lozenges in high caries risk schoolchildren. Clin Oral Investig. 2014;18(2):555-61. View abstract.

Dani C, Coviello C C, Corsini I I, Arena F, Antonelli A, Rossolini GM. Lactobacillus Sepsis and Probiotic Therapy in Newborns: Two New Cases and Literature Review. AJP Rep. 2016;6(1):e25-9. View abstract.

DE Sanctis V, Belgioia L, Cante D, et al. Lactobacillus brevis CD2 for prevention of oral mucositis in patients with head and neck tumors: A multicentric randomized study. Anticancer Res. 2019;39(4):1935-1942. View abstract.

Esaiassen E, Cavanagh P, Hjerde E, Simonsen GS, Støen R, Klingenberg C. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis 2016;22(9):1664-6. View abstract.

Fetrow CW, Avila JR. Professional's Handbook of Complementary & Alternative Medicines. 1st ed. Springhouse, PA: Springhouse Corp., 1999.

Franko B, Vaillant M, Recule C, Vautrin E, Brion JP, Pavese P. Lactobacillus paracasei endocarditis in a consumer of probiotics. Med Mal Infect 2013;43(4):171-3. View abstract.

Fuke N, Aizawa K, Suganuma H, Takagi T, Naito Y. Effect of combined consumption of Lactobacillus brevis KB290 and ß-carotene on minor diarrhoea-predominant irritable bowel syndrome-like symptoms in healthy subjects: a randomised, double-blind, placebo-controlled, parallel-group trial. Int J Food Sci Nutr. 2017;68(8):973-986. View abstract.

Goldin BR. Health Benefits of probiotics. Br J Nutr 1998;80:S203-7. View abstract.

Hemalatha R, Mastromarino P, Ramalaxmi BA, et al. Effectiveness of vaginal tablets containing lactobacilli versus pH tablets on vaginal health and inflammatory cytokines: a randomized, double-blind study. Eur J Clin Microbiol Infect Dis. 2012;31(11):3097-105. View abstract.

Holz C, Benning J, Schaudt M, et al. Novel bioactive from Lactobacillus brevis DSM17250 to stimulate the growth of Staphylococcus epidermidis: a pilot study. Benef Microbes. 2017;8(1):121-131. View abstract.

Kalima P, Masterton RG, Roddie PH, et al. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996;32:165-7. View abstract.

Kato K, Funabashi N, Takaoka H, et al. Lactobacillus paracasei endocarditis in a consumer of probiotics with advanced and severe bicuspid aortic valve stenosis complicated with diffuse left ventricular mid-layer fibrosis. Int J Cardiol 2016;224:157-61. View abstract.

Lai S, Lingström P, Cagetti MG, et al. Effect of Lactobacillus brevis CD2 containing lozenges and plaque pH and cariogenic bacteria in diabetic children: a randomised clinical trial. Clin Oral Investig. 2021;25(1):115-123. View abstract.

Liu AT, Chen S, Jena PK, Sheng L, Hu Y, Wan YY. Probiotics improve gastrointestinal function and life quality in pregnancy. Nutrients 2021;13(11):3931. View abstract.

Maekawa T, Hajishengallis G. Topical treatment with probiotic Lactobacillus brevis CD2 inhibits experimental periodontal inflammation and bone loss. J Periodontal Res. 2014;49(6):785-91. View abstract.

Meydani SN, Ha WK. Immunologic effects of yogurt. Am J Clin Nutr 2000;71:861-72. View abstract.

Mohseni AH, Taghinezhad-S S, Keyvani H, Ghobadi N. Comparison of Acyclovir and Multistrain Lactobacillus brevis in Women with Recurrent Genital Herpes Infections: a Double-Blind, Randomized, Controlled Study. Probiotics Antimicrob Proteins. 2018;10(4):740-747. View abstract.

Murakami K, Habukawa C, Nobuta Y, Moriguchi N, Takemura T. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial. Biopsychosoc Med. 2012;6(1):16. View abstract.

Nakakita Y, Tsuchimoto N, Takata Y, Nakamura T. Effect of dietary heat-killed Lactobacillus brevis SBC8803 (SBL88™) on sleep: a non-randomised, double blind, placebo-controlled, and crossover pilot study. Benef Microbes. 2016;7(4):501-9.View abstract.

Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.

Pillai A, Tan J, Paquette V, Panczuk J. Does probiotic bacteremia in premature infants impact clinically relevant outcomes? A case report and updated review of literature. Clin Nutr ESPEN. 2020;39:255-259. View abstract.

Poindexter B; Committee on fetus and newborn. Use of Probiotics in Preterm Infants. Pediatrics. 2021;147(6):e2021051485. View abstract.

Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178. View abstract.

Pudgar P, Pov&scaron;i&ccaron; K, &Ccaron;uk K, et al. Probiotic strains of Lactobacillus brevis and Lactobacillus plantarum as adjunct to non-surgical periodontal therapy: 3-month results of a randomized controlled clinical trial. Clin Oral Investig. 2021;25(3):1411-1422.View abstract.

Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60. View abstract.

Reznichenko H, Henyk N, Maliuk V, et al. Oral intake of Lactobacilli can be helpful in symptomatic bacterial vaginosis: A randomized clinical study. J Low Genit Tract Dis. 2020l;24(3):284-289. View abstract.

Riccia DN, Bizzini F, Perilli MG, et al. Anti-inflammatory effects of Lactobacillus brevis (CD2) on periodontal disease. Oral Dis. 2007;13(4):376-85. View abstract.

Roberfroid MB. Prebiotics and probiotics: are they functional foods? Am J Clin Nutr. 2000;71(6 Suppl):1682S-7S; discussion 1688S-90S. View abstract.

Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. View abstract.

Satomi S, Waki N, Arakawa C, Fujisawa K, Suzuki S, Suganuma H. Effects of heat-killed Levilactobacillus brevis KB290 in combination with ß-carotene on influenza virus infection in healthy adults: a randomized controlled trial. Nutrients 2021;13(9):3039. View abstract.

Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in southern Finland 1989-1992. Clin Infect Dis 1996;22:564-6. View abstract.

Sendil S, Shrimanker I, Mansoora Q, Goldman J, Nookala VK. Lactobacillus rhamnosus bacteremia in an immunocompromised renal transplant patient. Cureus. 2020;12(2):e6887. View abstract.

Sharma A, Rath GK, Chaudhary SP, Thakar A, Mohanti BK, Bahadur S. Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study. Eur J Cancer. 2012;48(6):875-81. View abstract.

Silva NLNV, Della Bona A, Cardoso M, et al. Lactobacillus brevis CD2 attenuates traumatic oral lesions induced by fixed orthodontic appliance: A randomized phase 2 trial. Orthod Craniofac Res. 2021;24(3):379-385. View abstract.

Stankovic M, Veljovic K, Popovic N, et al. Lactobacillus brevis BGZLS10-17 and Lb. plantarum BGPKM22 exhibit anti-inflammatory effect by attenuation of NF-?B and MAPK signaling in human bronchial epithelial cells. Int J Mol Sci. 2022;23(10):5547. View abstract.

Tasli L, Mat C, De Simone C, Yazici H. Lactobacilli lozenges in the management of oral ulcers of Behçet's syndrome. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S83-6. View abstract.

US Food and Drug Administration (FDA). Dear Healthcare Provider Letter: Warning Regarding Use of Probiotics in Preterm Infants. September 2023. Available at: https://www.fda.gov/media/172606/download?attachment. Accessed November 1, 2023.

Waki N, Matsumoto M, Fukui Y, Suganuma H. Effects of probiotic Lactobacillus brevis KB290 on incidence of influenza infection among schoolchildren: an open-label pilot study. Lett Appl Microbiol 2014;59(6):565-71. View abstract.

Zbinden A, Zbinden R, Berger C, Arlettaz R. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 2015;107(1):56-9. View abstract.

Zheng J, Wittouch S, Salvetti E, et al. A Taxonomic Note on the Genus Lactobacillus: Description of 23 Novel Genera, Emended Description of the Genus Lactobacillus Beijerinck 1901, and Union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol. 2020 Apr 15. doi:10.1099/ijsem.0.004107. View abstract.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.

Conditions

Drugs & Supplements

Well-Being

More

LEVILACTOBACILLUS BREVIS - Uses, Side Effects, and More